Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference (AAIC)

Business Wire July 27, 2016

vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference

Business Wire July 14, 2016

vTv Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

Business Wire July 6, 2016

vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions

Business Wire June 14, 2016

vTv Therapeutics Reports First Quarter Financial and Operational Results

Business Wire May 12, 2016

vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity

Business Wire April 20, 2016

vTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

Business Wire April 12, 2016

vTv Therapeutics to Present at the 15th Annual Needham Healthcare Conference

Business Wire April 6, 2016

vTv Therapeutics to Present at Two Investor Conferences in March

Business Wire March 4, 2016

vTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights

Business Wire March 1, 2016

vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273

Business Wire February 22, 2016

vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes

Business Wire February 9, 2016

vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

Business Wire January 28, 2016

vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

Business Wire January 21, 2016

Volatility Creates Opportunity, Insights on Price Data - Research on vTv Therapeutics, Golden Entertainment, NCI Inc., and Avinger Inc.

Accesswire December 7, 2015

Equity Market Movement at a Glance - Research on vTv Therapeutics, Golden Entertainment, NCI, and AVINGER

Accesswire November 27, 2015

vTv Therapeutics to Participate in Fireside Chat at Piper Jaffray 27th Annual Healthcare Conference

Business Wire November 24, 2015

vTv Therapeutics to Present at Stifel 2015 Healthcare Conference

Business Wire November 13, 2015

vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015

Business Wire November 12, 2015

vTv Therapeutics to Present at the 8th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Business Wire October 22, 2015